Research
Hormonal
Combination therapy of semaglutide (2.4 mg) and cagrilintide (2.4 mg) (CagriSema) produces weight loss (~15.6%) and HbA1c reduction (~2.2%) comparable to the highest dose of tirzepatide (15 mg) in patients with Type 2 Diabetes.
For patients with Type 2 Diabetes and obesity, a new combination injection (CagriSema) containing semaglutide and cagrilintide (both 2.4 mg weekly) achieves significant weight loss (15.6%) and blood sugar control (HbA1c reduction 2.2%), comparable to the highest dose of tirzepatide. This offers a potent option for those who need both glucose and weight management.
GoodSupportsHIGH confidence
a combination of semaglutide with cagrilintide in the same once weekly subcutaneous injection (each at a dose of 2.4mg: CagriSema) produced similar effects to the 15 mg dose of tirzepatide. The CagriSema reduced HbA1c by 2.2% and body weight by 15.6%
Why this rating
Based on Phase 2 trial data (REDEFINE programme).
Source
Recent advances in peptide-based therapies for obesity and type 2 diabetes
Clifford J. Bailey et al. · Peptides · 2024
DOI 10.1016/j.peptides.2024.171149
narrative_reviewCited 20×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.Strong
- Triple agonists (GLP-1/GIP/Glucagon) like retatrutide achieve even greater weight loss (>24%) than dual agonists, likely due to the addition of glucagon receptor agonism which increases energy expenditure.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →